Abstract:

Objective To evaluate the effectiveness of combined therapy with terazosin and tolterodine for patients with benign prostatic hyperplasia. Methods Seventy-four patients with benign prostatic hyperplasia without serious obstructive symptom were randomly assigned to terazosin group (treated with terazosin only, n=31) and combined therapy group (treated with terazosin and tolterodine, n=43). The International Prostate Symptoms Score (IPSS), score on the urinary storage phase symptoms, maximum urinary flow rate, mean voiding volume per 24 h, residual urine volume, number of micturation per 24 h, number of incontinence per 24 h and number of enuresis nocturna were obtained before and after treatment, and the adverse events were recorded. Results Twelve weeks after treatment, the IPSS, score on the urinary storage phase symptoms, residual urine volume, number of micturation per 24 h, number of incontinence per 24 h and number of enuresis nocturna significantly decreased in terazosin group （P＜0.05）, while maximum urinary flow rate and mean voiding volume significantly increased (P＜0.05）. There were significant differences in IPSS, score on the urinary storage phase symptoms, number of incontinence and number of enuresis nocturna between two groups after treatment （P＜0.05）. Conclusion Combined therapy with terazosin and tolterodine can well relieve the symptoms of benign prostatic hyperplasia without serious obstruction of urinary tract.

Key words: benign prostatic hyperplasia, terazosin, tolterodine